IL265970B - Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine - Google Patents
Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicineInfo
- Publication number
- IL265970B IL265970B IL265970A IL26597019A IL265970B IL 265970 B IL265970 B IL 265970B IL 265970 A IL265970 A IL 265970A IL 26597019 A IL26597019 A IL 26597019A IL 265970 B IL265970 B IL 265970B
- Authority
- IL
- Israel
- Prior art keywords
- medicine
- pharmaceutical compositions
- related compounds
- sulfoxyalkyl organonitro
- organonitro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408182P | 2016-10-14 | 2016-10-14 | |
| PCT/US2017/056454 WO2018071741A1 (en) | 2016-10-14 | 2017-10-13 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL265970A IL265970A (en) | 2019-06-30 |
| IL265970B true IL265970B (en) | 2022-03-01 |
Family
ID=61906413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL265970A IL265970B (en) | 2016-10-14 | 2019-04-11 | Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11008287B2 (enExample) |
| EP (1) | EP3526195A4 (enExample) |
| JP (1) | JP7332469B2 (enExample) |
| KR (1) | KR20190128619A (enExample) |
| CN (1) | CN110352190A (enExample) |
| AU (2) | AU2017342436C1 (enExample) |
| BR (1) | BR112019007453A2 (enExample) |
| CA (1) | CA3040479A1 (enExample) |
| EA (1) | EA201990949A1 (enExample) |
| IL (1) | IL265970B (enExample) |
| MX (1) | MX2019004280A (enExample) |
| SG (1) | SG11201903312VA (enExample) |
| WO (1) | WO2018071741A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| WO2013052803A2 (en) | 2011-10-07 | 2013-04-11 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| CN118236371A (zh) | 2016-01-11 | 2024-06-25 | 埃皮辛特瑞柯斯公司 | 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法 |
| EP3526195A4 (en) | 2016-10-14 | 2020-05-20 | EpicentRx, Inc. | SULFOXYALKYLE ORGANONITRO, RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE |
| IL271777B2 (en) | 2017-07-07 | 2024-09-01 | Epicentrx Inc | Compositions for parenteral administration of therapeutic agents |
| US11510901B2 (en) | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
| AU2022294071A1 (en) * | 2021-06-16 | 2024-01-04 | Epicentrx, Inc. | Organonitro and sulfoxyalkyl organonitro compounds for use in treating medical disorders |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2978453A (en) | 1956-12-12 | 1961-04-04 | Aerojet General Co | 3, 3, 5, 5-tetranitropiperidine |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS5511509A (en) | 1978-07-07 | 1980-01-26 | Toomasu Gorudon Robaato | Cancer therapy |
| US4935450A (en) | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| US4584130A (en) | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
| GB8728418D0 (en) | 1987-12-04 | 1988-01-13 | Jenkins T C | Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5693794A (en) | 1988-09-30 | 1997-12-02 | The United States Of America As Represented By The Secretary Of The Navy | Caged polynitramine compound |
| JP2659614B2 (ja) | 1990-11-13 | 1997-09-30 | 株式会社日立製作所 | 表示制御装置 |
| TW198712B (enExample) * | 1991-04-17 | 1993-01-21 | Hoffmann La Roche | |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| EP0611306B1 (en) | 1991-11-08 | 1998-07-08 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
| US5336784A (en) | 1993-06-07 | 1994-08-09 | The Regents Of The University Of California | Synthesis of 1,3,3-trinitroazetidine |
| WO1995032715A1 (en) | 1994-05-27 | 1995-12-07 | Neptune Pharmaceutical Corporation | Nitric oxide donor composition and method for treatment of anal disorders |
| WO1996028205A1 (en) | 1995-03-14 | 1996-09-19 | Siemens Aktiengesellschaft | Ultrasonic atomizer device with removable precision dosing unit |
| ES2140069T3 (es) | 1995-03-14 | 2000-02-16 | Siemens Ag | Dispositivo atomizador ultrasonico con unidad dosificadora de precision desmontable. |
| US5580988A (en) | 1995-05-15 | 1996-12-03 | The United States Of America As Represented By The Secretary Of The Army | Substituted azetidines and processes of using them |
| WO1996036602A1 (en) | 1995-05-15 | 1996-11-21 | The United States Of America | Adnaz, compositions and processes |
| US5898038A (en) | 1996-03-19 | 1999-04-27 | Board Of Regents, The University Of Texas System | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
| EP0932598A1 (en) | 1996-10-11 | 1999-08-04 | Warner-Lambert Company | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME |
| AU3129097A (en) | 1996-10-15 | 1998-05-11 | Eastman Chemical Company | Explosive formulations |
| GB9720797D0 (en) | 1997-09-30 | 1997-12-03 | Rhodes John | Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome |
| NZ504021A (en) | 1997-10-17 | 2003-04-29 | Systemic Pulmonary Delivery Lt | Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication |
| US6056966A (en) | 1998-05-18 | 2000-05-02 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for treating impotence |
| WO2000006143A1 (en) | 1998-07-27 | 2000-02-10 | Texas Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| US6391911B1 (en) | 1999-02-26 | 2002-05-21 | Robert E. Bases | Coadministration of lucanthone and radiation for treatment of cancer |
| US20020077276A1 (en) | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| US6245799B1 (en) | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| CZ20023213A3 (cs) | 2000-04-10 | 2003-12-17 | Pfizer Products Inc. | Benzoamidové piperidinové sloučeniny a příbuzné sloučeniny |
| US6861530B2 (en) | 2000-07-07 | 2005-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Piperidine derivatives |
| DE10111049A1 (de) | 2001-03-06 | 2002-09-12 | Beiersdorf Ag | Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| AU2003247792B2 (en) | 2002-07-03 | 2009-09-24 | Nicox S.A. | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| AU2003282534A1 (en) | 2002-10-07 | 2004-05-04 | Radiorx, Inc. | X-nitro compounds, pharmaceutical compositions thereof and uses therof |
| WO2004098538A2 (en) | 2003-03-13 | 2004-11-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods of use |
| CA2531543C (en) | 2003-06-25 | 2010-10-12 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them |
| AU2004255268B2 (en) | 2003-07-09 | 2010-04-01 | Loma Linda University | Use of nitrite salts for the treatment of cardiovascular conditions |
| GB0326047D0 (en) | 2003-11-07 | 2003-12-10 | Univ Sheffield | Substance |
| WO2006029385A2 (en) | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds. |
| US20060264415A1 (en) | 2005-04-01 | 2006-11-23 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| JP2009510073A (ja) | 2005-09-27 | 2009-03-12 | ノバルティス アクチエンゲゼルシャフト | カルボキシアミン化合物およびその使用方法 |
| GB0611405D0 (en) | 2006-06-09 | 2006-07-19 | Univ Belfast | FKBP-L: A novel inhibitor of angiogenesis |
| US8122281B2 (en) | 2007-04-13 | 2012-02-21 | International Business Machines Corporation | System and method for dependent failure-aware allocation of distributed data-processing systems |
| US8471041B2 (en) | 2010-02-09 | 2013-06-25 | Alliant Techsystems Inc. | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
| US20120149678A1 (en) | 2010-12-09 | 2012-06-14 | Oronsky Bryan T | Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto |
| US8664247B2 (en) * | 2011-08-26 | 2014-03-04 | Radiorx, Inc. | Acyclic organonitro compounds for use in treating cancer |
| ES2935573T3 (es) | 2011-10-07 | 2023-03-08 | Epicentrx Inc | Compuestos de organonitro tioéter y usos médicos de estos |
| WO2013052803A2 (en) | 2011-10-07 | 2013-04-11 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| CN118236371A (zh) | 2016-01-11 | 2024-06-25 | 埃皮辛特瑞柯斯公司 | 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法 |
| EP3526195A4 (en) | 2016-10-14 | 2020-05-20 | EpicentRx, Inc. | SULFOXYALKYLE ORGANONITRO, RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE |
| IL271777B2 (en) | 2017-07-07 | 2024-09-01 | Epicentrx Inc | Compositions for parenteral administration of therapeutic agents |
-
2017
- 2017-10-13 EP EP17859688.8A patent/EP3526195A4/en not_active Withdrawn
- 2017-10-13 WO PCT/US2017/056454 patent/WO2018071741A1/en not_active Ceased
- 2017-10-13 BR BR112019007453A patent/BR112019007453A2/pt not_active Application Discontinuation
- 2017-10-13 EA EA201990949A patent/EA201990949A1/ru unknown
- 2017-10-13 MX MX2019004280A patent/MX2019004280A/es unknown
- 2017-10-13 KR KR1020197013789A patent/KR20190128619A/ko not_active Withdrawn
- 2017-10-13 SG SG11201903312VA patent/SG11201903312VA/en unknown
- 2017-10-13 US US16/341,538 patent/US11008287B2/en active Active
- 2017-10-13 CA CA3040479A patent/CA3040479A1/en active Pending
- 2017-10-13 AU AU2017342436A patent/AU2017342436C1/en active Active
- 2017-10-13 JP JP2019519978A patent/JP7332469B2/ja active Active
- 2017-10-13 CN CN201780077202.8A patent/CN110352190A/zh active Pending
-
2019
- 2019-04-11 IL IL265970A patent/IL265970B/en unknown
-
2022
- 2022-05-12 AU AU2022203169A patent/AU2022203169B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3040479A1 (en) | 2018-04-19 |
| EA201990949A1 (ru) | 2019-10-31 |
| MX2019004280A (es) | 2019-09-18 |
| CN110352190A (zh) | 2019-10-18 |
| KR20190128619A (ko) | 2019-11-18 |
| AU2017342436A1 (en) | 2019-05-02 |
| SG11201903312VA (en) | 2019-05-30 |
| AU2022203169A1 (en) | 2022-06-02 |
| EP3526195A4 (en) | 2020-05-20 |
| AU2022203169B2 (en) | 2024-04-18 |
| US11008287B2 (en) | 2021-05-18 |
| IL265970A (en) | 2019-06-30 |
| AU2017342436B2 (en) | 2022-05-19 |
| US20200157047A1 (en) | 2020-05-21 |
| WO2018071741A1 (en) | 2018-04-19 |
| AU2017342436C1 (en) | 2022-11-03 |
| EP3526195A1 (en) | 2019-08-21 |
| WO2018071741A8 (en) | 2019-05-31 |
| BR112019007453A2 (pt) | 2019-07-16 |
| JP2019532067A (ja) | 2019-11-07 |
| JP7332469B2 (ja) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258082B (en) | History of benzaimidazole and pharmaceutical preparations containing them | |
| IL265970B (en) | Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine | |
| IL256085B (en) | A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment | |
| PL3515420T3 (pl) | Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek | |
| ZA201802125B (en) | Pharmaceutical composition and application thereof | |
| IL254552A0 (en) | Polycyclic carbamoylpyridone compounds and their pharmaceutical uses | |
| IL252477A0 (en) | 2-aminopyrimidine compound, pharmaceutical structure and its use | |
| IL252532A0 (en) | Polycyclic carbamoylpyridone compounds and their pharmaceutical use | |
| PT3412660T (pt) | Derivado de sulfonamida e composição farmacêutica contendo o mesmo | |
| EP3297640A4 (en) | Pharmaceutical co-crystal composition and use thereof | |
| SG11201605868XA (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| GB201701400D0 (en) | Compound for use in medicine | |
| PL3129057T3 (pl) | Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu | |
| SG10202106375UA (en) | Pharmaceutical compositions and use thereof | |
| PL3288933T3 (pl) | Związki oksindolowe i ich kompozycje farmaceutyczne | |
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| IL249440B (en) | Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| PL3250181T3 (pl) | Formulacja farmaceutyczna na bazie minoksydylu do stosowania miejscowego i jej zestaw | |
| GB201616880D0 (en) | Compound for use in medicine | |
| HK40013407A (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| PT3177283T (pt) | Composto ativo e composição relacionada pata utilização dermatológica no campo farmacêutico ou cosmético | |
| IL237283A0 (en) | Dldh and its derivatives, and preparations containing them for medical use | |
| ZA201903341B (en) | Pharmaceutical compositions and uses thereof | |
| IL264083A (en) | A pharmaceutical preparation containing benzydamine |